Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

NCT01994629 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease

Interventions

BIOLOGICAL: MenACWY-CRM
BIOLOGICAL: MenACWY-TT

Sponsor

Novartis Vaccines